AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04812977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)
Study NCT02107235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral rigosertib
Study NCT02107235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT02107235 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT02420509 — intervention group
Intervention type: DRUG
Intervention: systemic chemotherapy
Description: twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery
Study NCT02449902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: 1 10 µg capsule inserted vaginally for 14 days.
Study NCT02449902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 placebo capsule inserted vaginally for 14 days.
Study NCT00641797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meclizine
Description: medication administration 25mg PO one time
Study NCT00641797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epley Maneuver
Description: Patient has vestibular rehabilitation utilizing the Epley Maneuver.
Study NCT03214016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: 1 hour of Mat Pilates, 2 times a week, during 8 weeks.
Study NCT01811004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miraDry
Description: miraDry
Study NCT01552863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation F, single dose
Study NCT01811004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser
Description: Nd:YAG 1440 nm Laser
Study NCT01811004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Botox®
Description: Botox®
Study NCT00133965 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standard Palliative Care
Description: If you are in the Standard Palliative Care group you will receive the standard care that is usually provided here at Memorial Hospital. This can include services such as consultations by physicians, nurses and other healthcare professionals. In addition, referrals to community resources and services can also be made. The study period will be between five and seven days. At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires as described above. Total time commitment for this study should be approximately 60-90 minutes.
Study NCT02336321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BNCI controlled hand exoskeleton
Description: The BNCI system fuses and translates bio-signals related to user intention into control signals of an assistive device performing grasping motions
Study NCT02405182 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Study NCT00739713 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sea buckthorn (Hippophaë rhamnoides) oil
Description: Dosage 2 g/d, frequency twice/d, duration 3 months
Study NCT00739713 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparison
Description: Placebo comparison, dosage 2 g/d, frequency twice/d, duration 3 months
Study NCT03402061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: nutrient enhanced recipes
Description: normal ingredients will be substituted to promote nutrient density of products
Study NCT03080025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT® (Cognitively Based Compassion-Training)
Description: The CBCT® (Cognitively Based Compassion-Training) as a secular approach was established as a structured protocol.~The therapeutic tools are based on systemic approaches \& techniques, which contains a resource- \& solution orientation and the approach of Gottman's model of healthy relationships (e.g. trust and commitment - based on that - elements like the positive perspective).~Four dyadic exercises are introduced to enhance positive reciprocity between the romantic partners (based on concepts of couple communication training):~a) Building mindful ability to talk, b) building mindful ability to listen (without reacting initially), c) appreciation in action - indulging the partner, d) noticing, how the partner is doing something good for me - gratefulness in action verbally/non-verbally. Finally, the empathy exercise has been added inspired by CBASP therapy for chronic major depression.
Study NCT02135614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Presatovir
Description: Presatovir 200 mg (4 x 50 mg tablets) administered orally
Study NCT02135614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Presatovir placebo
Description: Presatovir placebo tablets administered orally
Study NCT02142608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR55
Description: Ultrasound contrast agent
Study NCT01634841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Walnuts
Description: 30 to 60g (1 to 2 oz) per day of walnuts
Study NCT01634841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: habitual diet
Description: Dietary information will be provided
Study NCT04579354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality tour
Description: Patients will be guided via VR on their way through the hospital to the operating theater
Study NCT00946738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: Biofeedback training as behaviour treatment was performed thrice weekly for 4 week.
Study NCT00946738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep oscillation
Description: Deep oscillation providing a pulsing electromagnetic field was performed thrice weekly for 4 weeks.
Study NCT00957827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: keflex
Description: keflex 500 mg BID 5 days
Study NCT00957827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo BID for five days
Study NCT05732324 — intervention group
Intervention type: PROCEDURE
Intervention: IVUS guided PCI optimization
Description: PCI to long lesion will be optimized according to the IVUS.
Study NCT02484937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2 (PCP Treatment)
Description: For the PCP group treatment will be performed (pain treatment/medications) by the Primary Care Physician in his/her office/clinic.
Study NCT02484937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 (PMS Treatment)
Description: For the PMS group treatment will be performed (pain treatment/medications) by the Pain Medicine Specialist in his/her office/clinic.
Study NCT05732324 — intervention group
Intervention type: PROCEDURE
Intervention: FFR guided PCI optimization
Description: PCI to long lesion will be optimized according to the FFR.
Study NCT05732324 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FFR measurement
Description: Fractional flow reserve protocol will be applied for both FFR-guided and IVUS-guided PCI groups. FFR will be measured according to the standard practice using intravenous adenosine. FFR will be recorded before PCI at the distal third of the coronary artery and after PCI at the same location. In FFR optimization group more than one post PCI FFR measurements could be acquired if the operators performed additional optimization. In IVUS optimization group only one post PCI FFR measurement will be recorded after which the procedure will be considered to be finished, and no further interventions will be undertaken. The same FFR measurements will be performed at 9-12 months follow-up.
Study NCT01053143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H1N1 pandemic influenza vaccine (non- adjuvanted)
Description: 0.5 mL, Intramuscular
Study NCT00081276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV
Study NCT00081276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00081276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04785547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: 15 mcg/m2/day for 28 days
Study NCT02352467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurix
Description: Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
Study NCT04451148 — intervention group
Intervention type: OTHER
Intervention: Obese with or without metabolic syndromesubjects
Description: Children with obesity and with or without metabolic syndrome
Study NCT00825760 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topical PPA904 gel and light
Study NCT00825760 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topical placebo gel plus light
Study NCT00815464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liquid Acupuncture (Herb Acupoint Injection)
Description: Each 4 weeks per one circle.The first 3 weeks for treatment practice(one per week)and the last week for test collection.
Study NCT03435887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alere q HIV-1/2 Detect for point of care infant testing
Description: The investigators will pilot the Alere q HIV-1/2 Detect mobile system for point of care (POC) infant testing at two of the study hospitals. A blood sample will be collected from each HIV-exposed infants at birth (before discharge from Maternity or at first follow-up MCH visit within 14 days postnatal) and at 6-week EID visit (4-8 weeks postnatal) for analysis with Alere q HIV-1/2 Detect, with results available within 1-2 hours to enable mother notification at the same clinic visit.
Study NCT03435887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GeneXpert HIV-1 Qual for point of care infant testing
Description: The investigators will pilot the GeneXpert HIV-1 Qual mobile system for point of care (POC) infant testing at two of the study hospitals. A blood sample will be collected from each HIV-exposed infants at birth (before discharge from Maternity or at first follow-up MCH visit within 14 days postnatal) and at 6-week EID visit (4 to \<24 weeks postnatal) for analysis with GeneXpert HIV-1 Qual, with results available within 1-2 hours to enable mother notification at the same clinic visit.
Study NCT03435887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV DNA PCR testing (Standard of Care)
Description: This is the standard of care for infant HIV testing. A dried blood spot sample will be collected from the infant and shipped to a central laboratory for HIV DNA PCR testing. Results will then be returned to the hospital.
Study NCT00728234 — intervention group
Intervention type: DEVICE
Intervention: aEEG recording
Description: weekly recordings with aEEG
Study NCT01358214 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire on Quality of Life.
Description: The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives. The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life. Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.
Study NCT00100828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT03395288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Mannose
Description: A total of 2 g D-mannose daily
Study NCT04935541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine infusion
Description: After Dexmedetomidine infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
Study NCT04935541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: After Remifentanil infusion was given for 10 minutes, local anesthesia was applied by the surgeon. Peribulbar block and periorbital infiltration application were performed by applying a mixture of lidocaine (Jetokain, Adeka, Turkey) and 1/200000 adrenaline. After the local anesthetic agent was applied by the surgeon, orbital compression was provided for 5 minutes with maximum pressure to block the eyelid movements. Cataract surgery procedures of all patients included in the study were performed by the same surgeon.
Study NCT00241670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid (5-ALA)
Description: 1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery
Study NCT00771498 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lopinavir
Description: ARV treatment: 2 NRTIs + lopinavir/r 800mg / 200 mg (4 tablets of Kaletra) every 12 hours, daily and orally Antituberculosis treatment: rifampin (600 mg/daily) + isoniazide (400 mg/daily) for 6 months, both in fasting condition + pirazinamide (2000 mg) for the first two months
Study NCT01213966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: po, single dose
Study NCT02166255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: siRNA-transfected peripheral blood mononuclear cells APN401
Description: Given IV
Study NCT02166255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01895777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
Study NCT01895777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
Study NCT00214383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS Internet telehealth
Description: CHESS Internet telehealth
Study NCT03348878 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: assessment of drug compliance
Description: assessment of drug compliance using electronic monitoring devices (2 months duration)
Study NCT01709500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMT (atorvastatin, simvastatin, or rosuvastatin)
Study NCT01709500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab
Description: Alirocumab administered as a subcutaneous (SC) injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Study NCT01709500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Study NCT03765450 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: Patients will receive infliximab at the discretion of their physician as part of standard of care.
Study NCT02303912 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nuc-1031 and Carboplatin
Description: Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days (Total 6 cycles)
Study NCT00721071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: After each subject has performed post-bronchodilator spirometry, he/she will inhale increasing concentrations of 3, 4, and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
Study NCT02780258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Silk
Study NCT03860974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serratus Plane block (single injection)
Description: A single-injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL of local anesthetic for unilateral surgery; 16 mL of local anesthetic each side for bilateral surgery).
Study NCT01552863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation G, single dose
Study NCT01552863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 5 mg PF-00345439 Formulation TBD, single dose
Study NCT01552863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation H, single dose
Study NCT02389036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDD Oral Paste
Description: A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
Study NCT01094821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-7505
Description: 3 mg three times daily for 9 days
Study NCT01094821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule three times daily for 9 days
Study NCT01094821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-7505
Description: 10 mg ATI-7505 three times daily for 9 days
Study NCT01094821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-7505
Description: 20 mg ATI-7505 three times daily for 9 days
Study NCT03610243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure
Description: Two 2-hour one-on-one training sessions in patient-centered self-administered acupressure will be provided by trainers in the first week (4 hours) in the patient's home or at the university, depending on his/her preference. From the second to fourth weeks of the intervention, participants will engage in 15 minutes of self-administered acupressure twice a day (for a total of 10.5 hours over the 3 weeks). They will log the frequency of self-practice in a diary and be encouraged to undertake self-practice beyond the 4-week intervention. At weeks 2, 3, and 4, a 1-hour follow-up visit will be conducted by the same team of trainers to reinforce learning and self-practice (for a total of 3 hours over the 3 weeks).
Study NCT00906191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-531
Study NCT00757835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment with latanoprost/timolol fixed combination
Description: dosing in the evening with the two fixed combinations
Study NCT00757835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost/timolol fixed combination drops
Description: once in the evening
Study NCT04046185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor combined progesterone
Description: Toripalimab combine with progesterone
Study NCT04046185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone
Description: progesterone
Study NCT02224495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise training
Study NCT03772574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facemask preoxygenation
Description: Standard facemask preoxygenation
Study NCT03282292 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal jugular vein CVC insertion
Description: Double lumen CVC insertion in the internal jugular vein
Study NCT03282292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal jugular vein CVC insertion
Description: Double lumen CVC insertion in the internal jugular vein
Study NCT03860974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block (single injection)
Description: Single injection paravertebral blocks will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL each side for bilateral surgery). For paravertebral blocks without axillary involvement, this will be at the T3 and T5 levels. For paravertebral blocks with axillary involvement, this will be at the T2 and T4 levels. For unilateral PVBs, 10 mL of local anesthetic will be injected per level. For bilateral paravertebral blocks, 8 mL of local anesthetic will be injected per level.
Study NCT00641797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam 1 - 5mg PO/IV prn
Study NCT02508636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given orally
Study NCT02508636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Given via intramuscular injection
Study NCT02508636 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: A total dose of 45 Gy in 25 fractions of 1.8 Gy each.
Study NCT03712410 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PISCES
Description: The intervention is based on Problem Solving Therapy and is a coping skills intervention designed for family caregivers of hospice patients.
Study NCT00962897 — intervention group
Intervention type: PROCEDURE
Intervention: Femoral-popliteal bypass
Description: Surgical bypass of blockage in the thigh